News Sentiment

ALKS sentiment intelligence

Alkermes Plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 51.94 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-4.8% over one week, +17.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS)

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -4.8% Price reacting lower
Trend fit Trend active 17.3% over four weeks
Fair value 74.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 38
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
simplywall.st 7
Stock Titan 6
Market source 6
Investing.com 4
Business Wire 3
GuruFocus 3
MSN 3
marketscreener.com 3

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 19
Deals and strategy 5
Analyst action 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 65
Business Wire Direct company coverage

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

Alkermes plc announced it will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting. The presentations will feature clinical and real-world data from their psychiatry and orexin portfolios, including commercial medicines LYBALVI and ARISTADA, a

Tone
Positive 65/100
Event
Market update
Published
27 May 2026 08:09
Source
Business Wire
MSN Direct company coverage

Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences

Alkermes will present data from its psychiatry portfolio and sleep research at various scientific conferences in the spring of 2026. These presentations will include a focus on real-world patient experiences, highlighting the company's commitment to advancing treatments in these

Tone
Positive 65/100
Event
Market update
Published
21 May 2026 17:09
Source
MSN
Citeline News & Insights Direct company coverage

Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH

Alkermes anticipates increased value from its acquisition of Avadel Pharmaceuticals following positive Phase III results for Lumryz in idiopathic hypersomnia (IH). However, due to a settlement with Jazz Pharmaceuticals, the launch of Lumryz is delayed until 2028. This development

Tone
Positive 67/100
Event
Deals and strategy
Published
12 May 2026 22:39
Source
Citeline News & Insights
Quantisnow Direct company coverage

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023

Alkermes plc is scheduled to report its fourth quarter and year-end financial results on February 16, 2023. The company's recent activities include various SEC filings, insider transactions, and upcoming financial results announcements for different quarters, as tracked by Quanti

Tone
Neutral 50/100
Event
Earnings
Published
12 May 2026 18:10
Source
Quantisnow
marketscreener.com Direct company coverage

Alkermes announces positive topline results from Revitalyz phase 3 study evaluating Lumryz

Alkermes plc announced positive topline results from its REVITALYZ Phase 3 study, which evaluated LUMRYZ (sodium oxybate) extended-release for adults with idiopathic hypersomnia. The study met its primary endpoint, demonstrating robust efficacy for the treatment. This development

Tone
Neutral 50/100
Event
Earnings
Published
12 May 2026 11:09
Source
marketscreener.com
MSN Direct company coverage

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

Alkermes (ALKS) reported strong first-quarter 2026 results, surpassing both earnings and revenue estimates. This positive financial performance led to a rise in the company's stock. The robust Q1 outcomes indicate a favorable outlook for the pharmaceutical company.

Tone
Positive 82/100
Event
Earnings
Published
11 May 2026 11:08
Source
MSN
Stock Titan Direct company coverage

ALKS Financials: Income Statement, Balance Sheet & Cash Flow

This article provides an in-depth financial analysis of Alkermes Plc (ALKS), including its income statement, balance sheet, cash flow statement, and key financial ratios through FY2025. It highlights the company's strong cash generation despite a decline in sales, maintaining hig

Tone
Neutral 50/100
Event
Balance sheet
Published
22 Apr 2026 17:09
Source
Stock Titan
富途牛牛 Direct company coverage

Alkermes to Report First Quarter Financial Results on May 5, 2026

Alkermes plc (Nasdaq: ALKS) announced that it will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. Interested part

Tone
Neutral 50/100
Event
Earnings
Published
22 Apr 2026 16:09
Source
富途牛牛
MarketBeat Direct company coverage

Tudor Investment Corp ET AL Takes Position in Alkermes plc $ALKS

Tudor Investment Corp ET AL has acquired a new stake in Alkermes plc (NASDAQ:ALKS), purchasing 56,383 shares valued at approximately $1.69 million in the third quarter. Despite this institutional interest and other funds increasing their positions, insiders have been selling shar

Tone
Neutral 50/100
Event
Earnings
Published
13 Apr 2026 12:10
Source
MarketBeat
Stock Titan Direct company coverage

[ARS] Alkermes plc. SEC Filing

This article reports on an ARS filing by Alkermes plc. (ALKS) on April 6, 2026, accessible as a PDF document. It provides an overview of the filing's low impact and neutral sentiment, along with recent news and other SEC filings related to Alkermes. The company's stock data, incl

Tone
Neutral 50/100
Event
Market update
Published
10 Apr 2026 15:39
Source
Stock Titan
GuruFocus Direct company coverage

Alkermes (ALKS) Advances Alixorexton into Phase 3 Trials for Narcolepsy Treatment

Alkermes (ALKS) has advanced alixorexton, an experimental oral treatment, into Phase 3 Brilliance Studies for narcolepsy types 1 and 2, building on positive Phase 2 results. The biotechnology company, with a market capitalization of $5.89 billion, demonstrates strong financial he

Tone
Positive 71/100
Event
Earnings
Published
01 Apr 2026 18:41
Source
GuruFocus
marketscreener.com Direct company coverage

Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating

Deutsche Bank has adjusted its price target for Alkermes plc (ALKS) from $43 to $42, while reiterating a Buy rating on the stock. This update reflects a minor change in the bank's valuation for the biopharmaceutical company. Alkermes recently completed the acquisition of Avadel P

Tone
Positive 60/100
Event
Deals and strategy
Published
18 Feb 2026 12:58
Source
marketscreener.com
Finviz - Stock Screener Direct company coverage

Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?

Alkermes (ALKS) is positioned for another earnings beat in its upcoming quarterly report, thanks to a strong history of surpassing analyst estimates and a favorable Zacks Earnings ESP of +1.54%. The company's average surprise in the last two quarters was 21.75%, and with a Zacks

Tone
Positive 70/100
Event
Earnings
Published
17 Feb 2026 18:27
Source
Finviz - Stock Screener
DirectorsTalk Interviews Direct company coverage

Alkermes plc (ALKS) Stock Analysis: Strong Buy Ratings and a Promising 32% Upside Potential

Alkermes plc (NASDAQ: ALKS) is highlighted as a compelling investment due to strong buy ratings and a projected 32.12% upside potential. The biopharmaceutical company, with a market cap of $5.48 billion, focuses on proprietary products for neurological disorders and mental health

Tone
Positive 75/100
Event
Market update
Published
16 Feb 2026 19:58
Source
DirectorsTalk Interviews
ALCHEMPro Direct company coverage

Ireland's Alkermes plc buys Avadel Pharmaceuticals plc

Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc for $2.3 billion in cash and debt, incorporating Avadel's FDA-approved narcolepsy drug, LUMRYZ, into its commercial portfolio. This strategic move expands Alkermes' presence in sleep medicine, enhances its p

Tone
Positive 81/100
Event
Deals and strategy
Published
16 Feb 2026 19:28
Source
ALCHEMPro
MarketBeat Direct company coverage

Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS

The Public Sector Pension Investment Board increased its stake in Alkermes plc by 11.6% in the third quarter, now owning 710,700 shares valued at $21.32 million. Institutional investors collectively own 95.21% of Alkermes stock. Analysts have a "Moderate Buy" consensus rating for

Tone
Positive 64/100
Event
Earnings
Published
14 Feb 2026 11:27
Source
MarketBeat
marketscreener.com Direct company coverage

Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement

Alkermes plc, along with Alkermes, Inc. and Alkermes Finance LLC, has entered into a credit agreement providing for two senior secured term loan facilities totaling $1.525 billion. These facilities, a $750 million TLA Facility and a $775 million TLB Facility, mature in February 2

Tone
Positive 59/100
Event
Balance sheet
Published
12 Feb 2026 13:56
Source
marketscreener.com